GlassScriptPhysician profile
Robert S Glickenberger
NPI 1407966690
$13,351.97
in general payments reported to CMS, 2019-2025
29 companies · $2,333 in 2025
The $2,333 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,971 · 2020: $1,536 · 2021: $1,048 · 2022: $1,729 · 2023: $1,881 · 2024: $1,855 · 2025: $2,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,970 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,969.89 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,016.14 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,671.03 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $1,394.20 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $615.94 | 2019-2025 | Entyvio, Gattex |
| Gilead Sciences, INC. | $539.80 | 2019-2025 | Epclusa |
| Phathom Pharmaceuticals, INC. | $538.40 | 2023-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $505.49 | 2019-2025 | |
| Braintree Laboratories, INC. | $348.72 | 2019-2020 | |
| Ardelyx, INC. | $312.59 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $296.97 | 2019-2025 | Linzess |
| Pfizer INC. | $279.12 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $266.04 | 2024-2025 | Zenpep |
| Daiichi Sankyo INC. | $257.87 | 2019-2023 | Injectafer |
| Nestle Healthcare Nutrition INC. | $233.78 | 2021-2023 | |
| Celgene Corporation | $226.65 | 2021-2024 | Zeposia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $155.26 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $133.40 | 2019-2023 | Dificid |
| Intuitive Surgical, INC. | $125.53 | 2025 | |
| Redhill Biopharma INC. | $88.20 | 2021 | |
| Ferring Pharmaceuticals INC. | $85.57 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $48.04 | 2024 | Iqirvo |
| Enterra Medical, INC. | $37.63 | 2025 | |
| Shire North American Group INC | $33.46 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $32.58 | 2025 | Dupixent |
| Madrigal Pharmaceuticals | $32.55 | 2025 | Rezdiffra |
| Allergan, INC. | $28.63 | 2019-2020 | |
| Olympus America INC. | $18.11 | 2019 | |
| Medtronic, INC. | $15.73 | 2023 | Bravo |
| Organon LLC | $14.54 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Glickenberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.